People · Operator
Named in public records as an officer, director or promoter · active 2016–2024 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Lb Pharmaceuticals Inc | — | Pharmaceuticals | Series D+ | $141.4M | $1.5B | 2020 |
| Elucida Oncology, Inc. | — | Biotechnology | Series B | $117.1M | $255.3M | 2020 |
| Elicio Therapeutics, Inc. | — | Biotechnology | Series B | $105.3M | $392.4M | 2019 |
| Aridis Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $56.6M | $63.0M | 2022 |
| X-Vax Technology, Inc. | — | Biotechnology | Series C | $56.6M | $2.3B | 2016 |
| Angion Biomedica Corp. | — | Biotechnology | Series B | $52.0M | $48.3M | 2023 |
| Nacuity Pharmaceuticals, Inc. | — | Biotechnology | Series A | $31.2M | $21.9M | 2021 |
| Sapience Therapeutics, Inc. | — | Biotechnology | Series B | $30.8M | $317.9M | 2020 |
Robert Ruffolo at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert Ruffolo on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Isaac Blech | 5 | 14 |
| Robert Connelly | 2 | 4 |
| Carol Ashe | 2 | 2 |
| Christopher Haqq | 2 | 2 |
| Julian Adams | 2 | 2 |
| Yekaterina Chudnovsky | 2 | 2 |
| Michael Smith | 1 | 20 |
| Chen Yu | 1 | 7 |
| Daniel Geffken | 1 | 6 |
| Jay Venkatesan | 1 | 5 |
| Michael T. Smith | 1 | 5 |
| Daniel Behr | 1 | 4 |
| Gerald Cagle | 1 | 4 |
| Roger Pomerantz | 1 | 4 |
| Ben Bronstein | 1 | 4 |
| Brian D. Finn | 1 | 4 |
| Roger J. Pomerantz | 1 | 4 |
| William Koster | 1 | 3 |
| Isaac A. Blech | 1 | 3 |
| Gary Sender | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.